Insider Selling: Natera (NASDAQ:NTRA) CEO Sells 5,079 Shares of Stock

Key Points

• Natera CEO Steven Leonard Chapman sold 5,079 shares of the company's stock on September 2nd for a total of $845,805.87, reducing his ownership by 3.10%.
• The company has a market capitalization of $23.06 billion and reported a revenue increase of 32.2% year-over-year, despite a negative EPS of ($0.74).
• Wall Street analysts remain optimistic about Natera, with the average price target set at $194.00, while some firms, like Morgan Stanley and Barclays, have issued "overweight" ratings.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 5,079 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $166.53, for a total value of $845,805.87. Following the completion of the sale, the chief executive officer directly owned 158,514 shares of the company's stock, valued at $26,397,336.42. This trade represents a 3.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, August 1st, Steven Leonard Chapman sold 5,807 shares of Natera stock. The shares were sold at an average price of $132.88, for a total value of $771,634.16.
• On Monday, July 28th, Steven Leonard Chapman sold 6,092 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $851,722.52.
• On Monday, July 21st, Steven Leonard Chapman sold 1,622 shares of Natera stock. The shares were sold at an average price of $139.29, for a total value of $225,928.38.
• On Tuesday, July 1st, Steven Leonard Chapman sold 5,343 shares of Natera stock. The shares were sold at an average price of $166.53, for a total value of $889,769.79.

Natera Trading Up 2.4%

Shares of NASDAQ:NTRA traded up $4.02 during mid-day trading on Thursday, hitting $173.81. 697,751 shares of the company traded hands, compared to its average volume of 1,473,024. The stock has a market cap of $23.86 billion, a P/E ratio of -91.00 and a beta of 1.68. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $183.00. The stock has a 50-day moving average price of $155.04 and a two-hundred day moving average price of $154.09.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm's quarterly revenue was up 32.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

Several hedge funds have recently made changes to their positions in the company. LRI Investments LLC bought a new stake in shares of Natera during the 4th quarter valued at $29,000. Bank of Jackson Hole Trust bought a new stake in shares of Natera during the 1st quarter valued at $29,000. Rakuten Securities Inc. raised its stake in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares during the period. ORG Partners LLC bought a new stake in shares of Natera during the 1st quarter valued at $32,000. Finally, TCTC Holdings LLC raised its stake in shares of Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on NTRA. Stephens reiterated an "overweight" rating and set a $183.00 price target on shares of Natera in a report on Friday, August 15th. Piper Sandler reiterated an "overweight" rating and set a $220.00 price target (up from $210.00) on shares of Natera in a report on Monday, August 11th. Cowen reiterated a "buy" rating on shares of Natera in a report on Friday, August 8th. Barclays reiterated an "overweight" rating and set a $210.00 price target (up from $190.00) on shares of Natera in a report on Friday, August 8th. Finally, Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $194.00.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.